Titel
Accueil
Navigation principale
Contenu
Recherche
Aide
Fonte
Standard
Gras
Identifiant
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Accueil
Plus de données
Partenaires
Aide
Mentions légales
D
F
E
La recherche est en cours.
Interrompre la recherche
Recherche de projets
Projet actuel
Projets récents
Graphiques
Identifiant
Titel
Titel
Unité de recherche
SEFRI
Numéro de projet
22.00257
Titre du projet
DNA replication at the heart of cell fate decisions and cancer development
Données de base
Textes
Participants
Titel
Textes relatifs à ce projet
Allemand
Français
Italien
Anglais
Résumé des résultats (Abstract)
-
-
-
Textes saisis
Catégorie
Texte
Résumé des résultats (Abstract)
(Anglais)
RepliFate is doctoral network designed to train the next generation of European researchers in the field of DNA replication, cell fate and cancer. We have designed an innovative training program that aims at providing interdisciplinary and intersectoral formation for the fellows. We base the network in inclusion, creativity and communication as the base to train the researchers in all aspects of scientific activity. RepliFate will investigate the mechanisms through which changes in DNA replication influence cell identity, respond to different kinds of stress, and prevent malignant transformation. We will put DNA replication at the center stage as the driver of these processes and not a mere bystander, using recent technological to better understand the role of DNA replication as a determinant of cell fate and cancer. RepliFate links academia with industry and society and will provide new opportunities for innovation in one of the main societal challenges in human health, cancer. The scientific roots of RepliFate are set on the Horizon Europe Mission Cancer objectives Understand and Optimise. We will pave the way for the development of innovative cancer treatments exploring the links between DNA replication and cell fate, the immune response and unscheduled cell proliferation. RepliFate is composed by 10 European beneficiaries (9 from academia and 1 from industry) along with 2 Swiss associated partners (with their own funding from the Swiss government), 4 companies, 1 news agency and 2 non-profit organizations as associated partners from 8 different countries. Putting the focus on the fellows, we have combined our expertise to create an outstanding training program with the objective to generate leaders in the field with independent and out-of-the-box views to drive the knowledge of basic science to applications that will improve the resilience of the European society by positively impacting on our response to the huge health challenge constituted by Cancer.
SEFRI
- Einsteinstrasse 2 - 3003 Berne -
Mentions légales